Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Marcos, TX
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Marcos, TX
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Arlington, VA
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Arlington, VA
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chesapeake, VA
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newport News, VA
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kennewick, WA
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Beckley, WV
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Beckley, WV
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
South Charleston, WV
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
South Charleston, WV
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, WI
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, WI
Click here to add this to my saved trials
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Onalaska, WI
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Onalaska, WI
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Austin Regional Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Accurate Clinical Management
mi
from
Houston, TX
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Accurate Clinical Management
mi
from
Houston, TX
Click here to add this to my saved trials
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  12/31/1969
Accurate Clinical Research
mi
from
Houston, TX
Usability of an AI for M923 in Subjects With Moderate to Severe RA
An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 12/31/1969
Accurate Clinical Research
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Medvin Clinical Research
mi
from
Covina, CA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Medvin Clinical Research
mi
from
Covina, CA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
MD Med Corp
mi
from
Hemet, CA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
MD Med Corp
mi
from
Hemet, CA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Joao Nascimento (Private Practice)
mi
from
Bridgeport, CT
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Joao Nascimento (Private Practice)
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Center for Arthritis and Osteoporosis
mi
from
Elizabethtown, KY
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Center for Arthritis and Osteoporosis
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology
mi
from
Mesa, AZ
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology
mi
from
Mesa, AZ
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Sun Valley Arthritis Center, Ltd
mi
from
Peoria, AZ
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Sun Valley Arthritis Center, Ltd
mi
from
Peoria, AZ
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Talbert Medical Group
mi
from
Huntington Beach, CA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Talbert Medical Group
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Denver Arthritis Clinic
mi
from
Denver, CO
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Denver Arthritis Clinic
mi
from
Denver, CO
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis and Rheumatic Disease Specialties
mi
from
Aventura, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis and Rheumatic Disease Specialties
mi
from
Aventura, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
RASF Clinical Research Center
mi
from
Boca Raton, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
RASF Clinical Research Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
QPS MRA (Miami Research Associates)
mi
from
Miami, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
QPS MRA (Miami Research Associates)
mi
from
Miami, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Omega Research Consultants Orlando
mi
from
Orlando, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Omega Research Consultants Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Family Clinical Trials, LLC
mi
from
Pembroke Pines, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Family Clinical Trials, LLC
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
McIlwain Medical Group
mi
from
Tampa, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
McIlwain Medical Group
mi
from
Tampa, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
BayCare Medical Group, Inc.
mi
from
Tampa, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
BayCare Medical Group, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Lovelace Scientific Resources
mi
from
Venice, FL
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Lovelace Scientific Resources
mi
from
Venice, FL
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Marietta Rheumatology Associates
mi
from
Marietta, GA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Marietta Rheumatology Associates
mi
from
Marietta, GA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis and Rheumatology Consultants, P.A.
mi
from
Edina, MN
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis and Rheumatology Consultants, P.A.
mi
from
Edina, MN
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center PRIME
mi
from
Lake Success, NY
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center PRIME
mi
from
Lake Success, NY
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Medication Management, LLC
mi
from
Greensboro, NC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Low Country Rheumatology, PA
mi
from
North Charleston, SC
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Low Country Rheumatology, PA
mi
from
North Charleston, SC
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
Sentara Medical Group, Clinical Research
mi
from
Norfolk, VA
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
Sentara Medical Group, Clinical Research
mi
from
Norfolk, VA
Click here to add this to my saved trials
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated:  12/31/1969
IMEDICA s.r.o.
mi
from
Brno,
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status: Enrolling
Updated: 12/31/1969
IMEDICA s.r.o.
mi
from
Brno,
Click here to add this to my saved trials